Latest News for: non-small cell lung cancer

Edit

Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | ...

GetNews 22 Aug 2025
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape.
Edit

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer (Bristol-Myers Squibb Company)

Public Technologies 18 Aug 2025
FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer ... Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases, which remains the leading cause of cancer-related death worldwide.
Edit

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

PR Newswire 18 Aug 2025
Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung ...
Edit

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, ...

GetNews 13 Aug 2025
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape.
Edit

C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline ...

GetNews 13 Aug 2025
DelveInsight’s, “C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape.
Edit

EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis ...

GetNews 13 Aug 2025
DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape.
Edit

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, ...

GetNews 13 Aug 2025
Download Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Sample report to know in detail about the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer treatment market @.
Edit

GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD (Form 8-K) (Verastem Inc)

Public Technologies 13 Aug 2025
GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the ... Efficacy and Safety of GFH375 in Advanced Non-Small Cell Lung Cancer Patients with KRAS G12D Mutation.
Edit

STUDY: Ultra-processed foods raise the risk of LUNG CANCER, non-small cell lung cancer and small ...

Natural News 12 Aug 2025
Cancer rates are on the rise globally, and the Big Food Industrial Complex is mostly to blame. Natural health advocates have been warning the world fo... .
Edit

Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment

The Galveston Daily News 11 Aug 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Aug 11, 2025-- ....
Edit

Non-Small Cell Lung Cancer Pipeline Outlook Report 2025: Key 100+ Companies and Breakthrough Therapies Shaping ...

GetNews 11 Aug 2025
Company name Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC) - Unmet Needs Non-Small-Cell Lung ...
Edit

Non-Small Cell Lung Cancer Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | AstraZeneca, Boehringer Ingelheim, ...

GetNews 30 Jul 2025
Non-Small Cell Lung Cancer market report covers a descriptive overview and comprehensive insight of the Non-Small Cell Lung Cancer Epidemiology and Non-Small Cell Lung Cancer market in the 7MM (the ...
Edit

MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer (Form 8-K) (Maia Biotechnology Inc)

Public Technologies 28 Jul 2025
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer ... for the treatment of non-small cell lung cancer (NSCLC).
Edit

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

PR Newswire 28 Jul 2025
... New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC).
Edit

Non-Small-Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Merck ...

GetNews 28 Jul 2025
DelveInsight’s, Non-Small-Cell Lung cancer (NSCLC) - Pipeline Insight, 2025,” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.

Article Search

tools
×
×
×
×